IP Library Granted Patent US 12,163,124
Granted Patent B2
US 12,163,124 · App. 17/195,625 · Granted Dec 10, 2024

Method for gene editing

Inventors: Hao Yin (Cambridge, MA); Wen Xue (Cambridge, MA); Daniel G. Anderson (Framingham, MA); Joseph R. Dorkin (Somerville, MA); Tyler E. Jacks (Newton, MA)
Assignee: Massachusetts Institute of Technology
C12N15/102A61K48/005C12N7/00C12N15/111C12N15/85C12N15/86C12N15/88C12N2310/20C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,163,124
App. No.
17/195,625
Granted
Dec 10, 2024
Kind
B2
Abstract

The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Claims (24)

1. A delivery system comprising:

a) an mRNA encoding a nucleic acid editing system provided in a first delivery vehicle; and

b) one or more guide RNA (gRNA) provided in a second delivery vehicle, wherein the first delivery vehicle is a lipid nanoparticle.

2. The delivery system of claim 1 , wherein the nucleic acid editing system is a CRISPR-Cas system.

3. The delivery system of claim 1 , wherein the nucleic acid editing system comprises Cas9.

4. The delivery system of claim 1 , wherein the mRNA encoding the nucleic acid editing system is chemically modified.

5. The delivery system of claim 1 , wherein the lipid nanoparticle comprises a lipophilic delivery compound.

6. The delivery system of claim 5 , wherein the lipophilic delivery compound comprises cKK-E12.

7. The delivery system of claim 1 , wherein the first and second delivery vehicles are the same delivery vehicles.

8. The delivery system of claim 1 , wherein the gRNA is chemically modified.

9. The delivery system of claim 1 , wherein the gRNA hybridizes to a target sequence associated with a genetic disease or disorder or a cancer in a cell in the subject, and wherein the genetic disease or disorder is an inborn error of metabolism selected from disorders of amino acid transport and metabolism, lipid or fatty acid transport and metabolism, carbohydrate transport and metabolism, and metal transport and metabolism.

10. The delivery system of claim 1 , further comprising a repair template.

11. The delivery system of claim 10 , wherein the repair template is selected from the group consisting of a DNA repair template, an mRNA repair template, a siRNA repair template, an miRNA repair template, and an antisense oligonucleotide repair template.

12. A method for modifying a target nucleotide sequence in a target tissue of a subject in need thereof, comprising administering to the subject:

a) an mRNA encoding a nucleic acid editing system provided in a first delivery vehicle; and

b) one or more guide RNA (gRNA) provided in a second delivery vehicle, wherein the first delivery vehicle is a lipid nanoparticle.

13. The method of claim 12 , wherein the nucleic acid editing system is a CRISPR-Cas system.

14. The method of claim 12 , wherein the nucleic acid editing system comprises Cas9.

15. The method of claim 12 , wherein the mRNA encoding the nucleic acid editing system is chemically modified.

16. The method of claim 12 , wherein the lipid nanoparticle comprises a lipophilic delivery compound.

17. The method of claim 16 , wherein the lipophilic delivery compound comprises cKK-E12.

18. The method of claim 12 , wherein the first and second delivery vehicles are the same delivery vehicles.

19. The method of claim 12 , wherein the gRNA is chemically modified.

20. The method of claim 12 , further comprising a repair template.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 2, 2023
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065431/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2022
From: YIN, HAO; XUE, WEN; ANDERSON, DANIEL G.; DORKIN, JOSEPH R.; JACKS, TYLER E.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 059431/0604 →
Continuity (7)
Continuation 16029273 · Jul 6, 2018
Continuation 15374227 · Dec 9, 2016
Continuation PCTUS2015035077 · Jun 10, 2015
Provisional Application 62010306 · Jun 10, 2014
Provisional Application 62113887 · Feb 9, 2015
Provisional Application 62156562 · May 4, 2015
Related Publication 20210324370A1 · Oct 21, 2021